1389 related articles for article (PubMed ID: 26037486)
41. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
42. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
43. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
Hutzschenreuter F; Monsef I; Kreuzer KA; Engert A; Skoetz N
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009310. PubMed ID: 26880256
[TBL] [Abstract][Full Text] [Related]
44. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
[TBL] [Abstract][Full Text] [Related]
45. Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.
Belhabri A; Thomas X; Troncy J; Assouline D; Michallet M; Wattel E; Tigaud JD; Blanc M; Fière D; Archimbaud E
Leuk Lymphoma; 1999 Dec; 36(1-2):45-55. PubMed ID: 10613449
[TBL] [Abstract][Full Text] [Related]
46. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.
Wang J; Yang YG; Zhou M; Xu JY; Zhang QG; Zhou RF; Chen B; Ouyang J
PLoS One; 2013; 8(4):e60699. PubMed ID: 23593285
[TBL] [Abstract][Full Text] [Related]
47. Bortezomib for the treatment of multiple myeloma.
Scott K; Hayden PJ; Will A; Wheatley K; Coyne I
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010816. PubMed ID: 27096326
[TBL] [Abstract][Full Text] [Related]
48. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Olaitan A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD010260. PubMed ID: 35994243
[TBL] [Abstract][Full Text] [Related]
49. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
50. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
51. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
52. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
54. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
[TBL] [Abstract][Full Text] [Related]
55. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
56. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
57. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
[TBL] [Abstract][Full Text] [Related]
58. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
59. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
[TBL] [Abstract][Full Text] [Related]
60. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]